Heron Therapeutics, Inc. Q3 2025 Earnings Recap

HRTX Q3 2025 November 5, 2025

Get alerts when HRTX reports next quarter

Heron Therapeutics reported a strong Q3 2025, generating net revenues of $38.2 million and achieving adjusted EBITDA of $1.5 million, highlighting significant growth in its acute care portfolio.

Earnings Per Share Miss

$-0.05 vs $-0.01 est.

-275.1% surprise

Revenue Miss

38213000 vs 39031250 est.

-2.1% surprise

Market Reaction

1-Day -2.63%

5-Day -2.63%

30-Day +1.75%

See HRTX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved 49% year-over-year growth in ZYNRELEF net sales, reaching $9.3 million in Q3 2025.
APONVIE sales surged 173% year-over-year, totaling $3 million, with a dedicated sales team now deployed.
Implemented successful initiatives, including the CrossLink Ignite program and the introduction of a product-specific J-code for ZYNRELEF, enhancing distributor engagement and reimbursement processes.
Continued strong performance in CINVANTI, maintaining steady demand despite competitive pressures.
Year-to-date revenues of $114.3 million, with positive momentum projected to continue into Q4 and beyond.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HRTX on AllInvestView.

Next Q1 2026